← Leaderboards
Roy Clifford Levitt
Genaera Corporation
$5,263,555
Attributed
$6,525,276
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2012–23$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$6,525,276 · 6
By mechanism
R01$2,523,442 · 1
UG3$1,516,241 · 1
UH3$1,109,446 · 1
R21$700,874 · 1
R44$575,273 · 1
R43$100,000 · 1
Top collaborators
- Eden R. Martin5 shared
Others in their field
Top investigators on “Receptor”
- Barton F Haynes · Duke University$182,835,224
- James C. Paulson · Scripps Research Institute$84,068,192
- Asrar B. Malik · University Of Illinois At Chicago$55,280,031
- Anthony O Caggiano · Cognition Therapeutics, Inc.$49,563,751
- Robert J Coffey · Vanderbilt University$48,115,270
- Robert H Vonderheide · University Of Pennsylvania$48,030,034
Research focus
ReceptorLeadCalciumDesignNeuronsCarbonate DehydrataseInositolResponseSignal TransductionOralValidationPersistent PainProgramsInhibitor/AntagonistCostTimelineChronic PainPainCalcium SignalingProteinsBasePathway InteractionsMeetingsIn Vitro
Grant awards (12)
Disease Modifying Analgesia with CA8 Gene Therapy$1,109,446
UH3 · FY2023 · NS · contact PI
Disease Modifying Analgesia with CA8 Gene Therapy$1,516,241
UG3 · FY2021 · NS · contact PI
Long Acting Local Analgesics: HSV-CA8 Biotherapeutics$371,577
R21 · FY2018 · NS · contact PI
Long Acting Local Analgesics: HSV-CA8 Biotherapeutics$329,297
R21 · FY2018 · NS · contact PI
CA8 Variants: New Mechanisms Underlying Transitions to Persistent Pain Syndromes$476,261
R01 · FY2016 · DE · contact PI
CA8 Variants: New Mechanisms Underlying Transitions to Persistent Pain Syndromes$479,794
R01 · FY2015 · DE · contact PI
CA8 Variants: New Mechanisms Underlying Transitions to Persistent Pain Syndromes$488,455
R01 · FY2014 · DE · contact PI
CA8 Variants: New Mechanisms Underlying Transitions to Persistent Pain Syndromes$537,705
R01 · FY2013 · DE · contact PI
CA8 Variants: New Mechanisms Underlying Transitions to Persistent Pain Syndromes$541,227
R01 · FY2012 · DE · contact PI
Aminosterol Compounds as Therapeutic for Asthma$152,967
R44 · FY2003 · HL
Aminosterol Compounds as Therapeutic for Asthma$422,306
R44 · FY2002 · HL
AMINOSTEROL COMPOUNDS AS THERAPEUTICS FOR ASTHMA$100,000
R43 · FY2000 · HL